NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Oasmia Pharmaceutical AB (publ) (PINK: OASMY)

 
OASMY Technical Analysis
5
As on 1st Jan 2026 OASMY STOCK Price closed @ 0.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.00 & Strong Sell for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

OASMYSTOCK Price

Open 0.05 Change Price %
High 0.05 1 Day -0.05 -100.00
Low 0.00 1 Week -0.05 -100.00
Close 0.00 1 Month -0.05 -100.00
Volume 1700 1 Year -0.05 -100.00
52 Week High 0.05 | 52 Week Low 0.00
 
PINK USA Most Active Stocks
IVDA 0.34 %
VNUE 0.00 %
SPOM 0.00 %
TXGE 3316.21 2.69%
KEGS 0.00 %
SUTI 0.00 %
HMBL 0.00 %
BRTX 0.28 %
TRSI 0.00 %
INKW 0.00 %
 
PINK USA Top Gainers Stocks
GLOH 3.75 37400.00%
ANAV 12.05 30025.00%
CEBUF 1.69 16800.00%
DLEXY 1.55 15400.00%
CGGYY 41.88 6765.57%
BKGM 950.00 6566.67%
GPGC 0.40 3900.00%
SJRNF 0.12 1100.00%
WMTN 1.00 900.00%
OGGNF 0.10 900.00%
 
PINK USA Top Losers Stocks
VSSSF 0.00 -100.00%
VRVR 0.00 -100.00%
VDKB 0.00 -100.00%
VADP 0.00 -100.00%
TPPM 0.00 -100.00%
TNPH 0.00 -100.00%
SZLSF 0.00 -100.00%
SKLV 0.06 -100.00%
SKLV 0.06 -100.00%
SAMMF 0.00 -100.00%
 
 
OASMY
Daily Charts
OASMY
Intraday Charts
Whats New @
Bazaartrend
OASMY
Free Analysis
 
OASMY Important Levels Intraday
RESISTANCE0.10
RESISTANCE0.07
RESISTANCE0.05
RESISTANCE0.03
SUPPORT-0.03
SUPPORT-0.05
SUPPORT-0.07
SUPPORT-0.10
 
OASMY Forecast February 2026
4th UP Forecast0.1
3rd UP Forecast0.07
2nd UP Forecast0.05
1st UP Forecast0.03
1st DOWN Forecast-0.03
2nd DOWN Forecast-0.05
3rd DOWN Forecast-0.07
4th DOWN Forecast-0.1
 
OASMY Weekly Forecast
4th UP Forecast0.10
3rd UP Forecast0.07
2nd UP Forecast0.05
1st UP Forecast0.03
1st DOWN Forecast-0.03
2nd DOWN Forecast-0.05
3rd DOWN Forecast-0.07
4th DOWN Forecast-0.10
 
OASMY Forecast2026
4th UP Forecast0.1
3rd UP Forecast0.07
2nd UP Forecast0.05
1st UP Forecast0.03
1st DOWN Forecast-0.03
2nd DOWN Forecast-0.05
3rd DOWN Forecast-0.07
4th DOWN Forecast-0.1
 
 
OASMY Other Details
Segment EQ
Market Capital 116950104.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
OASMY Address
OASMY
 
OASMY Latest News
 
Your Comments and Response on Oasmia Pharmaceutical AB (publ)
 
OASMY Business Profile
Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer. Its products portfolio includes Docetaxel micellar, a patented formulation that combines XR-17 with docetaxel that has completed pre-clinical trial for the treatment of prostate cancer; and Cantrixil, which has completed Phase I clinical trial for the treatment of ovarian cancer. The company also provides combination therapies, such as XR-19 for various forms of cancer, including ovarian, first-line breast, prostate, and lung cancer. In addition, its animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Oasmia Pharmaceutical AB (publ) was incorporated in 1988 and is headquartered in Uppsala, Sweden. Address: Vallongatan 1, Uppsala, Sweden, 752 28
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service